ArticleSurgery today2026
Feasibility and outcomes of curative-intent surgery for clinically node-positive non-small cell lung cancer with interstitial lung disease.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the feasibility and outcomes of curative-intent surgery in patients with clinically node-positive non-small cell lung cancer (NCSLC) and interstitial lung disease (ILD).
methodsWe retrospectively evaluated patients with clinically node-positive NSCLC and ILD, who underwent curative-intent surgery between 2012 and 2022. Survival outcomes and complications were also assessed. Risk stratification for acute exacerbations of ILD (AE-ILD) was performed using the Japanese Association for Chest Surgery (JACS) score.
resultsTwenty-eight patients were included in the study. Postoperative AE-ILD developed in 17.9% of patients within 30 days and 25.0% within 90 days. The incidence was lower in the low-risk group than in the intermediate-risk group (30 days: 12.5 vs. 20.0%; 90 days: 12.5 vs. 30.0%). No ILD-related deaths occurred within one year postoperatively in the low-risk group, whereas 71.4% of the deaths in the intermediate-risk group were ILD-related. The median overall survival (OS) and recurrence-free survival (RFS) were 19.5 and 13.7 months, respectively. Patients with cN1 or cN2a had favorable outcomes (OS: 28.5 and 28.6 months; RFS: 13.7 and 28.6 months, respectively), whereas those with cN2b showed poor survival (OS/RFS: 2.4 months).
conclusionsCurative-intent surgery may offer survival benefits for selected patients, particularly those with limited nodal disease and a low risk of AE-ILD.
Indexed as
Identifiers
41094278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.